Hycroft Mining Holding Stock (NASDAQ: HYMCW)

Latest news for Hycroft Mining Holding (NASDAQ:HYMCW) Stock

Hycroft Mining Holding Corp is a gold and silver producer. Its operating mine, the Hycroft Mine, is an open-pit heap leach operation located approximately fifty four miles west of Winnemucca, Nevada.

Hycroft Mining Holding Corporation - Warrant

Hycroft Mining Holding Corp

RAPT Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $0.85 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 76,452,000 shares of common stock at a price per pre-funded warrant of&nbsp;$0.8499, for gross proceeds of approximately $150.0 million. The private placement is expected to close on or about December 27, 2024, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise price of&nbsp;$0.0001&nbsp;per share of common stock, be immediately exercisable and remain exercisable until exercised in full.
The private placement was led by The Column Group and TCGX, with participation by new and existing investors including BVF Partners LP, Deep Track Capital, Foresite Capital, Medicxi, OrbiMed, Perceptive Advisors, Redmile Group and RTW Investments.
Net proceeds from the private placement are expected to fund the research and development of the Company's pipeline and for general corporate purposes.

News

Offerings

RAPT

RAPT Therapeutics To Raise $150M in Private Placement to Advance Drug Pipeline

Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), a leading global provider of payments and financial services technology, today announced it has entered into a definitive agreement to acquire Payfare Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PAY#TSX">PAY</a>), a provider of program management solutions with a particular focus on new economy workforces. The transaction is subject to obtaining shareholder and court approvals and other customary closing conditions and is expected to close in the first half of 2025.
This acquisition complements the embedded finance solutions of Fiserv with card program management, a white-label consumer app, and a microservices orchestration layer. These Payfare offerings, combined with the strengths of Fiserv in processing, bank ledgers and integrated value-added services, enhance the Fiserv solution in embedded banking, payments and lending and help meet needs of large enterprises and financial institutions.
"Payfare has built a reputation as an innovator in workforce payments for gig-economy companies," said Frank Bisignano, Chairman, President and Chief Executive Officer of Fiserv. "Together, we can accelerate the delivery of embedded finance solutions for all of our clients, empowering their next chapter of success. We look forward to welcoming the talented Payfare team to Fiserv."
"Joining Fiserv is a tremendous opportunity for Payfare," said Marco Margiotta, CEO and Founding Partner of Payfare. "We recognize that Fiserv gives us enhanced scale and technology which better positions us to serve a growing number of large organizations and deliver a modern digital experience."

TSX:PAY

Fiserv to Acquire Payfare, Strengthening Gig Economy Payment Solutions

Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced progress in the development of its investigational one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu.
"The spread of avian influenza in wild and domestic animal populations including mammals, brings increasing risk for adaptation to humans and subsequent spread in the population" said Robert R. Redfield, MD, Chief Medical Officer for Traws Pharma and former Director of the U.S. Centers for Disease Control and Prevention (CDC). "Bird flu is an occupational hazard for poultry and dairy workers. With increasing numbers of human infections and recent reports of severe cases, we should be alert to the rising potential for epidemic or pandemic spread of bird flu."
"In laboratory testing, tivoxavir marboxil inhibited multiple isolates of highly pathogenic avian influenza H5N1. We evaluated the effects of drug treatment in mice exposed to human H5N1, where the virus was isolated from a dairy worker exposed to infected cattle," said C. David Pauza, PhD, Chief Science Officer for Traws Pharma. "Oral treatment with tivoxavir marboxil after the virus infection resulted in complete survival and lung virus levels below the limit of quantitation1. This result is highly encouraging for future clinical development of tivoxavir marboxil for treating human H5N1 influenza."

TRAW

Traws Pharma Advances One-Dose Bird Flu Treatment with Results

D. Boral Capital analyst Jason Kolbert initiates coverage on Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announces Price Target of $36.

Price Target

Initiation

Analyst Ratings

OMER

D. Boral Capital Initiates Coverage On Omeros with Buy Rating, Announces Price Target of $36

HSDT

Helius Secures First PoNS System Sale To Veterans Affairs, Advancing MS Gait Therapy For U.S. Veterans

Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa&#x2122; (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive, sight-threatening corneal disease.
"The NDA submission for Epioxa represents an important milestone for our company as it brings us one step closer in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye," said Thomas Burns, Glaukos chairman and chief executive officer. "We look forward to working closely with the FDA in their pending review process and continue to believe Epioxa, which is designed to reduce procedure times, improve patient comfort and shorten recovery time,represents a potentially meaningful advancement in the treatment paradigm for patients suffering from keratoconus."

Government

Regulations

GKOS

Glaukos Seeks FDA Approval for Non-Invasive Keratoconus Therapy Epioxa

D. Boral Capital analyst Jason Kolbert initiates coverage on Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy rating and announces Price Target of $32.

CMPX

D. Boral Capital Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $32

<a href="https://www.globenewswire.com/Tracker?data=qew_wVgWX_vHMlpArWea1LUZ93LCUsjxRNhS0gW4nUvbaprdKQ1PdFmGa3vCzNXjouFUlqeGoDRDZlMf_MKav_jkyfiuD-G65HTm5nXYF2WEgZPWJFIcGG4aEdYMP3-MjMi9mK4qNU5cmG94yIIqK_1104sUJTOwVIabqjF4hxvAiQuCKTQSDZi6czOJnNlA">Immunocore Holdings plc (NASDAQ:</a><a href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that the first patient has been dosed in the Phase 1 trial of IMC-P115C (PRAME-HLE-A02), which is a half-life extended ImmTAC candidate.
IMC-P115C was developed to improve patient convenience by reducing the frequency of treatment administration. It is Immunocore's first half-life extended candidate, and sixth ImmTAC candidate to enter the clinic. IMC-P115C is a PRAME x CD3 ImmTAC bispecific protein, with the same CD3 and targeting the same HLA-A&#x2A;02:01 PRAME (PReferentially expressed Antigen in MElanoma) peptide as brenetafusp.

IMCR

Immunocore Advances Half-Life Extended Cancer Treatment with First Patient Dosed

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.laserphotonics.com%2F&amp;esheet=54170279&amp;newsitemid=20241223663585&amp;lan=en-US&amp;anchor=Laser+Photonics+Corporation&amp;index=1&amp;md5=3715c11cb515309fd94c03d1671c25d0">Laser Photonics Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) (LPC), a leading global developer of industrial laser systems for cleaning and other material processing applications, announced today that it received an order from the Cooper Nuclear Station (CNS), Nebraska's largest single-unit generator providing clean and reliable electricity.
"Laser cleaning technology is rapidly gaining ground as a highly effective alternative to hazardous surface preparation methods," said John Armstrong, Executive Vice President of Laser Photonics. "LPC is serving a growing number of clients in the nuclear energy sector, and we are thrilled that Cooper Nuclear entrusted us in providing its team with innovative laser-powered equipment."
The <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Flaserphotonics.com%2Flaser-systems%2Fhandheld-laser-cleaning-systems%2Fcleantech-commercial-roughening-laser-3010&amp;esheet=54170279&amp;newsitemid=20241223663585&amp;lan=en-US&amp;anchor=CleanTech+CR-3010&amp;index=3&amp;md5=648ce4909d9533b57b919a5cb1725e6b">CleanTech CR-3010</a>, acquired by CNS, is a commercial-grade handheld continuous wave fiber laser machine for surface preparation. It effectively removes contaminants and coatings off various surfaces during maintenance and production processes, and it has demonstrated its capability to blast off radioactive particles along with unwanted material. Paired with a fume extractor, the system turns into an irreplaceable power tool for the regular maintenance of equipment and infrastructure.
CNS, operated by the Nebraska Public Power District (NPPD), plans to use the CleanTech CR-3010 for paint and rust removal in the pre-weld preparation of valves, pipes and steel plates across plant equipment.

LASE

Laser Photonics Secures Nuclear Sector Deal with Cooper Station for Laser Tech

Brookline Capital analyst Leah Rush initiates coverage on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy rating.

EXEL

Brookline Capital Initiates Coverage On Exelixis with Buy Rating

RAPT Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, and Shanghai Jemincare Pharmaceutical Co., Ltd ("Jemincare"), a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China, today announced they have entered into an exclusive license agreement for JYB1904 (RAPT designation RPT904), a clinical-stage, half-life extended anti-immunoglobulin E (IgE) monoclonal antibody. Under the terms of the license agreement, RAPT is granted worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan (together, the "Jemincare Territory") to develop and commercialize RPT904. As consideration for the license, Jemincare receives a $35 million upfront license fee, up to $672.5 million in additional payments upon the achievement of various regulatory and commercial milestones, and royalties on future sales of RPT904 outside the Jemincare Territory. RPT904 is being developed to offer patients a potentially improved therapeutic option compared to omalizumab (marketed as Xolair&#xAE;), an anti-IgE monoclonal antibody approved for several allergic disorders, including asthma, chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps and, most recently, food allergy. RAPT plans to pursue development of RPT904 initially in food allergy. Separately, Jemincare is conducting Phase 2 clinical trials of JYB1904 in China in asthma and CSU.

RAPT Therapeutics Secures Global Rights to Develop Advanced Allergy Treatment

William Blair analyst Sami Corwin downgrades Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) from Outperform to Market Perform.

Downgrades

APLT

William Blair Downgrades Applied Therapeutics to Market Perform

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54170145&amp;newsitemid=20241220275848&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=814dbbfcfedd077b1a40fd2444cad63a">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving ACR20 response (at least a 20 percent improvement in signs and symptoms of disease) after 16 weeks of treatment compared with placebo.
Additionally, the POETYK PsA-1 and POETYK PsA-2 trials met important secondary endpoints across PsA disease activity at Week 16. The overall safety profile of Sotyktu through 16 weeks of treatment in the POETYK PsA-1 and POETYK PsA-2 trials was consistent with the established safety profile of Sotyktu observed in a Phase 2 PsA clinical trial and Phase 3 moderate-to-severe plaque psoriasis clinical trials.

Bristol Myers Squibb's Sotyktu Shows Results in Psoriatic Arthritis Trials

Ratings for Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) were provided by 22 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Estee Lauder Cos and provided 12-month price targets. The average target is $90.91, accompanied by a high estimate of $130.00 and a low estimate of $70.00. A decline of 14.36% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1734955232_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Estee Lauder Cos among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$81.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$81.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$75.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Bryan Spillane</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jason English</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$81.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$76.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Christopher Carey</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$122.00</td>
<td>$114.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Estee Lauder Cos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Estee Lauder Cos compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Estee Lauder Cos's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Estee Lauder Cos's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Estee Lauder Cos analyst ratings.</a>
<h2>Get to Know Estee Lauder Cos Better</h2>
Estee Lauder is a leader in the global prestige beauty market, participating across skin care (51% of fiscal 2024 sales), makeup (29%), fragrance (16%), and hair care (4%) categories, with top-selling brands such as Estee Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 30% of revenue from the Americas, 39% from Europe, the Middle East and Africa (including travel retail), and 31% from Asia-Pacific. Estee Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
<h3>Estee Lauder Cos: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Decline in Revenue: Over the 3 months period, Estee Lauder Cos faced challenges, resulting in a decline of approximately -4.46% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Estee Lauder Cos's net margin is impressive, surpassing industry averages. With a net margin of -4.64%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Estee Lauder Cos's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.0% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.73%, the company showcases effective utilization of assets.
Debt Management: Estee Lauder Cos's debt-to-equity ratio stands notably higher than the industry average, reaching 1.97. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

22 Analysts Have This To Say About Estee Lauder Cos

SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for SoundHound AI, revealing an average target of $12.64, a high estimate of $26.00, and a low estimate of $7.00. This upward trend is apparent, with the current average reflecting a 53.96% increase from the previous average price target of $8.21.
<img src="https://www.benzinga.com/files/images/story/2024/1734955224_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive SoundHound AI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Glenn Mattson</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Glenn Mattson</td>
<td>Ladenburg Thalmann</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.50</td>
<td>$9.50</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to SoundHound AI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SoundHound AI compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for SoundHound AI's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into SoundHound AI's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SOUN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on SoundHound AI analyst ratings.</a>
<h2>Unveiling the Story Behind SoundHound AI</h2>
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers.
<h3>Key Indicators: SoundHound AI's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: SoundHound AI's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 89.13%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: SoundHound AI's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -86.68%, the company may face hurdles in effective cost management.
Return on Equity (ROE): SoundHound AI's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -8.37%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -5.68%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: SoundHound AI's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.15.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SOUN

Forecasting The Future: 7 Analyst Projections For SoundHound AI

During the last three months, 4 analysts shared their evaluations of NCR Atleos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $42.25, a high estimate of $57.00, and a low estimate of $31.00. Witnessing a positive shift, the current average has risen by 9.74% from the previous average price target of $38.50.
<img src="https://www.benzinga.com/files/images/story/2024/1734955217_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of NCR Atleos by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dominick Gabriele</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Summerville</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NCR Atleos. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NCR Atleos compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of NCR Atleos's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into NCR Atleos's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NATL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NCR Atleos analyst ratings.</a>
<h2>Get to Know NCR Atleos Better</h2>
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a global customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. They manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications &amp; Technology.
<h3>Financial Milestones: NCR Atleos's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: NCR Atleos's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 1.03%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: NCR Atleos's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.23%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 9.34%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): NCR Atleos's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.42%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 11.73, NCR Atleos faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NATL

Expert Outlook: NCR Atleos Through The Eyes Of 4 Analysts

He made a fortune from water and now, according to the New York Post, Shark Tank investor Rohan Oza is spending $13.51 million in cash to live beside it. The striped Art Deco waterfront mansion in Miami Beach that Oza recently purchased might look like it was taken out of a bygone era, but there&#8217;s nothing old-school about Oza&#8217;s wealth. He made his cash from several recent popular brands that have become staples on supermarket shelves.
Oza&#8217;s new <a href="https://www.benzinga.com/real-estate/24/10/41453235/even-after-hurricane-helene-and-milton-south-floridas-luxury-market-sees-prices-rise-9-6">Miami Beach</a> home was built in 1936 and sculpted by architect Lawrence Murray Dixon, who owned it as a personal residence. Dixon is best known for designing the Raleigh, the Tides and other noted Art Deco buildings in South Beach. The 3,756-square-foot property contains six bedrooms and four bathrooms and enjoys a pool and dock.<a href="https://therealdeal.com/miami/2024/12/16/shark-tank-investor-drops-14m-on-miami-beach-house/">&nbsp;</a>
Don't Miss:
<ul>
<li>CEO of Integris gathered a team of senior investment managers who have $34.22 billion in combined owned and managed assets in the West Coast —<a href="https://www.benzinga.com/money/integris"> here&#8217;s how to invest in their private credit fund that targets 12% annual interest rate.</a></li>
<li><a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.<a href="https://www.benzinga.com/go/arrived-private-credit-yf"> </a></li>
</ul>
The Real Deal states that Oza&#8217;s Gaadi, a Montana LLC, bought the home at 214 West San Marino Drive from Villa Madison, a Florida entity managed by art gallery owners Rudolf and Nicole Budja. The Budjas previously listed the house for $29 million in 2022, reducing the price four times to its most recent listing of $13.5 million. Not surprisingly, according to broker Douglas Elliman, Oza doesn&#8217;t plan to keep the house as it is but tear it down and build a new waterfront palace.
<h2 class="wp-block-heading">The Brandfather</h2>
Dubbed &#8220;the Brandfather,&#8221; Oza – a 53-year-old Zambian-born, English-educated groundbreaking ad man – recognized the importance of celebrity branding. Early on, he involved singers and rappers to help raise the profile of his products, most notably Sprite, using the tagline &#8220;Obey Your Thirst,&#8221; sending sales soaring.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">Oza's Financial Masterstroke</h2>
Oza&#8217;s financial masterstroke came when he was the chief marketing officer for Glaceau, the parent company for Smartwater and Vitaminwater. He recruited rapper <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39228603/50-cents-bitcoin-earnings-a-journey-from-animal-ambition-to-millions">50 Cent</a> to be involved with the drink&#8217;s marketing. Subsequently, he sold Glaceau to his former employer, <a href="https://www.benzinga.com/general/entertainment/24/04/38143433/why-coca-cola-tastes-different-in-every-country">Coca-Cola</a>, for $4.1 billion in 2007. 50 Cent was estimated to have made between $75-$100 million from the deal, after taxes.&nbsp;
In addition, Oza cofounded the venture capital firm Cavu Consumer Partners with Brett Thomas in 2015. Their enviable portfolio of popular food and drink brands includes Oatly, Beyond Meat, Health-Ade Kombucha, Skinny Dipped, Osea, Poppi, Hims and Hers, Bulletproof Coffee, Vita Coco and many more. Another of Oza&#8217;s notable investments was the beverage company Bai Brands, which he sold to the Dr Pepper Snapple Group for $1.7 billion.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes-y2">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
<h2 class="wp-block-heading">$400 Million Net Worth</h2>
The purchase price of Oza&#8217;s new home would hardly cause a ripple to his financial standing as the Shark Tank investor is estimated to be worth anywhere between $200-$400 million, according to which website you read and accordingly has a history of high-priced real estate deals. He purchased a 6,000-square-foot home in <a href="https://www.benzinga.com/markets/24/12/42483873/sylvester-stallone-gifts-a-knockout-25-million-hamptons-estate-to-his-daughters-another-addition-to-his-curated-property-portfolio">Bridgehampton</a>, New York, which he sold in 2018 for $8.25 million. In 2010, Oza paid $12.5 million for a Beverly Hills mansion, which he rented periodically for $70-$100,000 monthly. In September 2024, it was sold for $21 million.
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes-y2"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a></li>
</ul>

Markets

From Water Bottles To Waterfront Mansions: Shark Tank Investor And Former Vitaminwater Exec, Rohan Oza Snaps Up Art Deco Miami Beach Home

During the last three months, 8 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.5, a high estimate of $10.00, and a low estimate of $6.00. This current average has decreased by 5.56% from the previous average price target of $9.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1734955209_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Lexicon Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lexicon Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lexicon Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Lexicon Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Lexicon Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LXRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lexicon Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Lexicon Pharmaceuticals</h2>
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
<h3>Understanding the Numbers: Lexicon Pharmaceuticals's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Lexicon Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 980.25%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -3703.49%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -30.97%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Lexicon Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -18.66%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Lexicon Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 0.57. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LXRX

Analyst Expectations For Lexicon Pharmaceuticals's Future

Castellum, Inc. (the "Company") (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 9,473,700 shares of common stock in a registered direct offering. The shares of common stock are being sold at an offering price of $0.38 per share.
The gross proceeds to the Company from the registered direct offering are estimated to be approximately $3.6 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about December 24, 2024, subject to the satisfaction of customary closing conditions.

Castellum Prices $3.6M Registered Direct Offering Of 9.47M Shares At $0.38/Share

The Biden administration has launched a trade investigation into Chinese-produced &#8220;legacy&#8221; semiconductors. This action, announced on Monday, could pave the way for higher U.S. tariffs on these essential components used in numerous consumer products.
What Happened: The &#8220;Section 301&#8221; investigation is slated to transition to the incoming administration of President-elect Donald Trump for completion. This could provide Trump with a chance to enforce the hefty 60% tariffs he has previously threatened on Chinese imports, Reuters reported on Monday.
Currently, a 50% U.S. tariff on Chinese semiconductors is set to begin on Jan. 1. The U.S. has also intensified export restrictions on advanced AI and memory chips to China, alongside increasing tariffs on other Chinese goods.
See Also: <a href="https://www.benzinga.com/markets/24/12/42572520/2025-housing-market-looks-like-a-year-of-struggle-for-states-like-builders-now-hold-record-inventory?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;2025 Housing Market Looks Like A Year Of Struggle For States Like …&#8217; – Builders Now Hold Record Inventory</a>
The U.S. Trade Representative&#8217;s office, led by Katherine Tai, explained that the probe seeks to shield market-driven chip producers from China&#8217;s state-driven expansion. Tai highlighted evidence of China&#8217;s attempts to dominate the semiconductor industry, similar to its strategies in other sectors.
The Biden administration will start&nbsp;accepting public comments on the&nbsp;probe on January 6, with a public hearing scheduled for March. The investigation will also evaluate the impact of these chips on critical industries, including defense and automotive sectors.
Why It Matters: This latest probe is part of a broader strategy by the Biden administration to curb China&#8217;s influence in the semiconductor industry. Earlier this month, the administration <a href="https://www.benzinga.com/government/regulations/24/12/42265847/biden-targets-china-with-new-chip-restrictions-nvidia-slides">implemented its third crackdown</a> on China&#8217;s semiconductor sector within three years, citing national security concerns. This initiative imposed export restrictions on 140 Chinese entities, including chip equipment manufacturers such as Naura Technology Group, targeting advanced memory chips and chipmaking tools. As a result, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) saw its stock trade lower due to potential impacts on its sales in China.
In response, China swiftly retaliated by tightening <a href="https://www.benzinga.com/news/global/24/12/42303132/china-retaliates-against-us-chip-sanctions-tightens-mineral-exports">controls on critical minerals</a> used in chip manufacturing, such as gallium, germanium, and antimony. These materials are crucial for advanced electronics and defense applications. The Chinese Ministry of Commerce justified these measures as necessary for national security, highlighting the escalating tensions between the two nations.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42638957/warren-buffetts-timeless-advice-if-youre-gonna-do-dumb-things-because-your-stock-goes-down-you-shouldnt-own-a-stock-at-all?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Warren Buffett's Timeless Advice For Investing $10,000: &#8216;If You're Gonna Do Dumb Things Because Your Stock At All&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

Comments

Hycroft Mining Holding

News

Latest news for Hycroft Mining Holding (NASDAQ:HYMCW) Stock

People Also Watch

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga